Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Merck Fosamax Study Shows Benefit Vs. Actonel; Aventis/P&G Fault Endpoint

Executive Summary

A Merck head-to-head trial showing an efficacy advantage for its osteoporosis agent Fosamax versus Actonel is "misleading" because the claim is based on bone mineral density rather than the preferred fracture risk endpoint, competitors maintain

You may also be interested in...



Roche/GSK Boniva Launch Plan Includes Reminders For Once-Monthly Dose

Roche and GlaxoSmithKline will support the launch of the osteoporosis therapy Boniva (ibandronate) with a program intended to help patients comply with the once-monthly oral dosing regimen

Roche/GSK Boniva Launch Plan Includes Reminders For Once-Monthly Dose

Roche and GlaxoSmithKline will support the launch of the osteoporosis therapy Boniva (ibandronate) with a program intended to help patients comply with the once-monthly oral dosing regimen

Merck Sales Force More Focused, Not Smaller, After Vioxx Withdrawal

Merck sales reps will detail fewer products to fewer doctors under a reorganized structure, the company told analysts during its investor day Dec. 14

Related Content

UsernamePublicRestriction

Register

PS044767

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel